OPICAPONE
| Brand name | ONGENTYS |
|---|---|
| Active ingredient | OPICAPONE |
| Strength | 25MG |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | April 2020 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9630955 | December 2032 | substance, product |
| 12129247 | January 2032 | use U-4038 |
| 10071085 | March 2030 | product |
| 10583130 | March 2030 | use U-3869 |
| 8524746 | July 2029 | use U-3869 |
| 8168793 | April 2029 | substance, product |
| 9745290 | October 2027 | product |
| 8907099 | May 2027 | substance |
| 9550759 | July 2026 | use U-3872 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.